{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:20Z","timestamp":1790791520960,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ijgc-2023-004924","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:35:25Z","timestamp":1702596925000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01609556","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02631876","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04296890","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04209855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02606305","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02606305","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02606305","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05041257","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04274426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04606914","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05445778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04606914","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05797168","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05041257","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04274426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04606914","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05445778","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8373-8569","authenticated-orcid":false,"given":"Giorgio","family":"Bogani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"Toon","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-6992","authenticated-orcid":false,"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004924_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092408","article-title":"Detection of ovarian cancer through exhaled breath by electronic nose: a prospective study","volume":"12","author":"Raspagliesi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004924_bb0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004924_bb0020","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004924_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0030","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004924_bb0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer Intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0040","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1136\/ijgc-2023-004924_bb0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.22.00291","article-title":"A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer (Study 006)","volume":"41","author":"Tanyi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0065","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/ijgc-2022-003701","article-title":"Integrating antibody drug conjugates in the management of gynecologic cancers","volume":"33","author":"Chelariu-Raicu","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004924_bb0070","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004924_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/cpb.52.1","article-title":"Recent developments in the maytansinoid antitumor agents","volume":"52","author":"Cassady","year":"2004","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1136\/ijgc-2023-004924_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/GCO.0000000000000838","article-title":"Advances in antibody-drug conjugates for gynecologic malignancies","volume":"35","author":"Tymon-Rosario","year":"2023","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004924_bb0085","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0095","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1B escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"17_suppl","key":"10.1136\/ijgc-2023-004924_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","volume":"41","author":"Moore","year":"2023","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004924_bb0115","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.annonc.2020.08.972","volume":"31","author":"O\u2019Malley","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0120","unstructured":"NIH, U.S National Library of Medicine ClinicalTrial.gov . Mirvetuximab soravtansine monotherapy in platinum-sensitive epithelial, peritoneal, and fallopian tube cancers (PICCOLO). Available: https:\/\/clinicaltrials.gov\/study\/NCT05041257 [Accessed 7 Oct 2023]."},{"key":"10.1136\/ijgc-2023-004924_bb0125","unstructured":"NIH, U.S National Library of Medicine ClinicalTrial.gov . Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR\u03b1) high recurrent ovarian cancer (MIROVA). Available: https:\/\/clinicaltrials.gov\/study\/NCT04274426 [Accessed 7 Oct 2023]."},{"key":"10.1136\/ijgc-2023-004924_bb0130","unstructured":"NIH, U.S. National Library of Medicine ClinicalTrial.gov . Study of carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy with advanced-stage ovarian, fallopian tube or primary peritoneal cancer. Available: https:\/\/clinicaltrials.gov\/study\/NCT04606914 [Accessed 7 Oct 2023]."},{"key":"10.1136\/ijgc-2023-004924_bb0135","unstructured":"NIH, U.S National Library of Medicine ClinicalTrial.gov . Mirvetuximab soravtansine with bevacizumab versus bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or peritoneal cancer (GLORIOSA). Available: https:\/\/clinicaltrials.gov\/study\/NCT05445778 [Accessed 7 Oct 2023]."},{"key":"10.1136\/ijgc-2023-004924_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ygyno.2023.07.010","article-title":"Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma","volume":"176","author":"Saito","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"16_suppl","key":"10.1136\/ijgc-2023-004924_bb0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5550","article-title":"Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1\/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance","volume":"41","author":"Harter","year":"2023","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004924_bb0150","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.annonc.2022.08.003","article-title":"Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?","volume":"33","author":"Kristeleit","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004924_bb0155","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004924_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100952","article-title":"Tisotumab vedotin in recurrent or metastatic cervical cancer","volume":"47","author":"Bogani","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"10.1136\/ijgc-2023-004924_bb0165","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004924_bb0170","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2023-004924_bb0175","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive advanced solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004924_bb0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:33Z","timestamp":1753234173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24013495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1048891X24013495"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004924","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}